Alpha 2.0
Login Register
» Authors » Satoshi Moriya

Satoshi Moriya

Explore the profile of Satoshi Moriya including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 38
Citations 296
Followers 0
Related Specialties
Gastroenterology
Oncology
Radiology
Top 10 Co-Authors
Shin Maeda
Kazushi Numata
Manabu Morimoto
Akito Nozaki
Makoto Chuma
Katsuaki Tanaka
Makoto Ueno
Satoshi Kobayashi
Masaaki Kondo
Hiroyuki Fukuda
Published In
Hepatol Res
Abdom Radiol (NY)
Eur J Radiol
Medicine (Baltimore)
Eur J Gastroenterol Hepatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Directional intermodular coupling enriches functional complexity in biological neuronal networks
Monma N, Yamamoto H, Fujiwara N, Murota H, Moriya S, Hirano-Iwata A, et al.
Neural Netw . 2025 Jan; 184:106967. PMID: 39756118
Hierarchically modular organization is a canonical network topology that is evolutionarily conserved in the nervous systems of animals. Within the network, neurons form directional connections defined by the growth of...
2.
Comparison of early wound healing using modified papilla preservation technique between enamel matrix derivative and recombinant human fibroblast growth factor
Nakayama Y, Tabe S, Igarashi K, Moriya S, Katsumata T, Kobayashi R, et al.
J Periodontal Implant Sci . 2023 Nov; 54(4):236-252. PMID: 38014774
Purpose: Enamel matrix derivative (EMD) has demonstrated beneficial effects on wound healing following surgery. However, the effects of recombinant human fibroblast growth factor 2 (rhFGF-2) in periodontal regeneration therapy have...
3.
Biological neurons act as generalization filters in reservoir computing
Sumi T, Yamamoto H, Katori Y, Ito K, Moriya S, Konno T, et al.
Proc Natl Acad Sci U S A . 2023 Jun; 120(25):e2217008120. PMID: 37307467
Reservoir computing is a machine learning paradigm that transforms the transient dynamics of high-dimensional nonlinear systems for processing time-series data. Although the paradigm was initially proposed to model information processing...
4.
Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection
Ideno N, Nozaki A, Chuma M, Ogushi K, Hara K, Moriya S, et al.
Eur J Gastroenterol Hepatol . 2022 Dec; 35(2):219-226. PMID: 36574313
Objectives: Toinvestigate liver carcinogenesis and other causes of death by collecting clinical data, including the Fib-4 index, from patients with successfully eradicated hepatitis C virus (HCV) by direct-acting antivirals (DAA)...
5.
Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study
Tozuka Y, Ueno M, Kobayashi S, Morimoto M, Fukushima T, Sano Y, et al.
Oncol Lett . 2022 Oct; 24(4):375. PMID: 36238838
Sarcopenia often affects patients with various types of cancer, and has been reported to affect patient prognosis and therapeutic effects. However, to the best of our knowledge, there are no...
6.
Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study
Wang F, Numata K, Komiyama S, Miwa H, Sugimori K, Ogushi K, et al.
Front Oncol . 2022 May; 12:843680. PMID: 35600400
Background: The present study aimed to evaluate the efficacy and safety of combined lenvatinib (first-line systemic therapy) and radiofrequency ablation (RFA) therapy in patients with intermediate-stage hepatocellular carcinoma with beyond...
7.
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, et al.
BMC Cancer . 2022 May; 22(1):517. PMID: 35525913
Background: Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased...
8.
Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients
Ogushi K, Chuma M, Numata K, Nozaki A, Moriya S, Uojima H, et al.
Eur J Gastroenterol Hepatol . 2022 Feb; 34(7):774-781. PMID: 35102114
Background: In this study, we investigated the impact of simple measurement of psoas muscle index (PMI) on the tolerability of sorafenib treatment of switch from sorafenib to regorafenib. Method: This...
9.
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, et al.
Hepatol Res . 2021 Nov; 52(3):269-280. PMID: 34761470
Purpose: To assess the impact of clinical factors on the safety and efficacy of atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular carcinoma (u-HCC). Method: Ninety-four...
10.
Comparison of Sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma
Wang F, Numata K, Okada M, Chuma M, Nihonmatsu H, Moriya S, et al.
Quant Imaging Med Surg . 2021 Jun; 11(6):2521-2540. PMID: 34079721
Background: This study aimed to compare the value of Sonazoid contrast-enhanced ultrasound (SCEUS) with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging (EOB-MRI) for histological grading diagnosis, especially for early hepatocellular carcinoma...